Defining the cellular microenvironment of sarcopenia in pancreatic cancer associated cachexia

Defining the cellular microenvironment of sarcopenia in pancreatic cancer associated cachexia - SarkoMap

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038650

Enrollment

Registered

2025-12-10

Start date

2026-01-02

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

R64

Interventions

Group 1: Control group: Living kidney donors - skeletal muscle tissue was collected intraoperatively Group 2: Pancreatic cancer patients without cachexia (defined by body weight development over the l

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Written informed consent Ability to give consent Pancreatic cancer Planned abdominal surgery Unintentional weight loss (yes and no)

Exclusion criteria

Exclusion criteria: Weight-modulating drugs (ozempic, mirtazapine, etc.) Weight-modulating surgeries Chronic inflammatory diseases (IBS, rheumatic diseases, sarcoidosis, tuberculosis, COPD, etc.) Other cancers Revocation of written consent

Design outcomes

Primary

Measure	Time frame
Since this is a non-interventional observational study with tissue collection for exploratory purposes, neither primary nor secondary endpoints are defined. The main objective of the study is to characterize local changes in skeletal muscle tissue in the context of pancreatic cancer-associated cachexia at the single-cell level. A secondary objective is to correlate the obtained results with postoperative weight progression, survival rate, quality of life, and the occurrence of tumor recurrence.	—

Measure

Time frame

Since this is a non-interventional observational study with tissue collection for exploratory purposes, neither primary nor secondary endpoints are defined. The main objective of the study is to characterize local changes in skeletal muscle tissue in the context of pancreatic cancer-associated cachexia at the single-cell level. A secondary objective is to correlate the obtained results with postoperative weight progression, survival rate, quality of life, and the occurrence of tumor recurrence.

—

Countries

Germany

Contacts

Public ContactMax Heckler

Universitätsklinikum Heidelberg

max.heckler@med.uni-heidelberg.de+4917643574069

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026